^
    Back
    Association details:
    Biomarker:SPARC overexpression
    Cancer:Ewing Sarcoma
    Drug:albumin-bound paclitaxel (Bcl2 inhibitor, Tubulin inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    GEIS 39: Phase II trial of nabpaclitaxel for the treatment of patient with multiply relapsed/refractory desmoplastic small round cell tumor (DSRCT) and Ewing sarcoma (EwS).

    Published date:
    05/19/2021
    Excerpt:
    Central pathology review selected for tumors with > Grade 3 (intense and diffuse) expression of SPARC by immunohistochemistry to be eligible....In the EwS cohort an ORR of 33.3% (all partial responses, median duration 2 months) and 16.7% of stabilizations were achieved....Single agent nab-paclitaxel in biomarker selected EwS patients, but not in DSRCT, provided clinically meaningful activity that deserves further development.
    DOI:
    10.1200/JCO.2021.39.15_suppl.11529
    Trial ID:
    2016-002464-14
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    J Control Release
    Title:

    SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas

    Published date:
    12/30/2021
    Excerpt:
    We confirmed such SPARC-mediated long-term intratumoral accumulation of nab-paclitaxel in Ewing sarcoma PDX with high expression of SPARC, which accumulated significantly more nab-paclitaxel than SPARC-low PDX. SPARC-high PDX responded better to nab-paclitaxel than SPARC-low tumors...
    DOI:
    10.1016/j.jconrel.2021.12.035